PLUS1
0.19
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 316 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Athenex Inc | ATNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.19 | 04:00:38 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.19 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 316 | - | 0.1184 - 1.20 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:00:17 | 13 | $ 0.19 | USD |
Period:
Draw Mode:
Athenex Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 29.91M | 157.41M | 121.85M | $ 120.18M | $ -89.55M | -1.92 | -0.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 742.63k | 5.30% |
Athenex News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1811 | 0.1958 | 0.18 | 0.1870927 | 889,270 | 0.0089 | 4.91% |
| 1 Month | 0.17 | 0.1959 | 0.165 | 0.1836972 | 1,350,386 | 0.02 | 11.76% |
| 3 Months | 0.195 | 0.30 | 0.1184 | 0.1640708 | 4,303,433 | -0.005 | -2.56% |
| 6 Months | 0.52 | 1.19 | 0.1184 | 0.2909473 | 3,008,471 | -0.33 | -63.46% |
| 1 Year | 1.07 | 1.20 | 0.1184 | 0.3744727 | 1,988,891 | -0.88 | -82.24% |
| 3 Years | 13.35 | 15.67 | 0.1184 | 3.92 | 1,790,627 | -13.16 | -98.58% |
| 5 Years | 14.52 | 22.00 | 0.1184 | 5.63 | 1,280,053 | -14.33 | -98.69% |
Athenex Description
| Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. |